Best 5 Companies in the Facial Injectables Market in 2025

With expanding urbanization, the disposable income of people has increased, and they are investing in aesthetic treatments with minimal invasiveness. One of these treatments is facial injectables, which use dermal fillers and other products to boost facial features and make the skin look suppler. Owing to this factor, facial injectables, such as botulinum toxin and dermal fillers, are witnessing a rising adoption by men, which can be attributed to their ability to efficiently reverse the early signs of gravitational aging that occur on the face. This factor has bolstered the uptake of cosmetic procedures. The demographic has experienced that age can have an adverse impact on facial appearance over time.

One key trend observed in the facial injectables space is that the male demographic is expressing increasing interest in minimally or non-invasive procedures. According to a 2022 survey by the International Society of Aesthetic Plastic Surgery, the male population was responsible for nearly 14.3% of the total non-surgical procedures carried out globally. Dermatologists are paying more attention to this population; thus, the proportion of males going through cosmetic procedures may surge in the future.

This, along with the rising demand for minimally invasive cosmetic procedures, is creating ample growth prospects for the market. People are looking for pain-free and convenient cosmetic procedures to avoid the side effects related to invasive surgeries. The American Society of Plastic Surgeons report stated that 8,736,591 minimally invasive cosmetic procedures deploying neuromodulator injections in 2022, a spike of 73.2% compared to 2019.

As per a report by Fortune Business Insights™, the market for facial injectables reached USD 8.93 billion in 2023 and is set to reach USD 17.24 billion by 2032 with a CAGR of 7.7% during the 2024-2032 forecast period.

In terms of the competitive scenario, the market has a consolidated structure and is led by some of the best facial injectables companies such as Galderma, Merz Pharma, and Allergan Aesthetics (AbbVie Inc.).

Fortune Business Insights™ Profiles 5 Best Facial Injectables Suppliers in the Market

1. Allergan Aesthetics (AbbVie, Inc.)

Allergan Aesthetics (AbbVie, Inc.) is a prominent company in the market with a varied product portfolio of facial injectables, such as the cosmetic neurotoxin of Botox Cosmetic and the hyaluronic acid fillers range of the Juvederm Collection. It is involved in consistent R&D initiatives to release innovative facial injectables. In 2023, the company’s revenue hit USD 54.32 billion, with its aesthetics segment generating revenue of USD 5.30 billion. In March 2024, the company’s JUVÉDERM VOLUMA XC, which is a hyaluronic acid derma filler to enhance moderate to critical temple hollowing, secured approval from the U.S. FDA.

2. GALDERMA

GALDERMA is a Swiss pharmaceutical firm with expertise in skincare products. It is the second-largest firm in the market. It has a varied portfolio of products for consumer and medicinal skin brands. The company has more than 50 operating sites in over 40 nations, including 4 manufacturing facilities. With respect to facial injectables, its major products are Sculptra, Azzalure, Dysport, Alluzience, and Restylane. It is also deeply focused on the creation of novel injectable aesthetic products and taking part in events to boost its presence in the market. In May 2024, the company released Restylane VOLYME, which is its hyaluronic acid injectable filler, in China to correct mid-face volume deficit/mid-face contour deficiency.

3. Merz Pharma

Merz Pharma is a German pharmaceutical company with is considered the third-largest name in the market. It is involved in the production, manufacturing, and development of pharmaceutical products and facial injectables. It operates under various segments, such as aesthetics, life care, and therapeutics. Its product offerings include a skincare range, a cutting-edge cellulite treatment, a skin-tightening and lifting device, dermal fillers, and botulinum toxin. Some of its major facial injectables include Xeomin, Belotero, and Radiesse. It intensely emphasizes R&D initiatives to get positive clinical trial outcomes and launch innovative products. In June 2023, the company unveiled that it has achieved positive Phase 3 results, which show that XEOMIN (incobotulinumtoxinA) is efficacious and safe for the treatment of upper facial lines.

4. Ipsen Pharma

Ipsen Pharma is a global pharmaceutical firm and the fourth leading name in the market. This French firm has an emphasis on the creation of specialty care products and innovative therapeutics through its three key therapeutic segments, including neuroscience, oncology, and rare diseases. It is present in 80 nations, with direct commercial availability in over 35 countries.  Its key facial injectable product is the cosmetic neurotoxin Dysport (abobotulinumtoxinA). In 2023, its revenue reached USD 3.38 billion. In October 2023, the company conducted late-stage phase II clinical trials to offer assurance of the efficacy and safety of IPN 10200 in the adult population for the treatment of moderate to severe facial lines.

5. Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology firm and holds the fifth position in the market. It is involved in the manufacturing, commercialization, and development of neuromodulators for different therapeutic and aesthetic indications in the U.S. and the world. Some of its prominent commercialized products include the cosmetic neuromodulator DAXXIFY and the RHA Collection. In 2023, the company’s revenue was USD 0.23 billion. In October 2022, it displayed the clinical data for the efficacy and safety profile of DAXXIFY in the injection form at the American Society for Dermatologic Surgery (ASDS) Annual Meeting.

How are Growing R&D Initiatives Paving the Way for Market Growth?

Consumers are becoming increasingly aware of their skin and health wellness. In this regard, manufacturers are investing significant amounts in R&D to launch enhanced capabilities of facial injectables to cater to the varying needs of consumers. These products find various aesthetic applications, and a rise in the number of application areas in the form of different kinds of minimally or non-invasive cosmetic procedures is expected to propel the market growth. The growing research studies for facial injectable products and their positive outcomes, along with recent regulatory clearances for these solutions, are further impelling the market expansion.